In vivo non-invasive 3D quantitative IVIS Spectrum molecular imaging system
In vivo non-invasive 3D quantitative IVIS Spectrum molecular imaging system
批准号:
7791805
负责人:
Evan T Keller
金额:
$35.99万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-02-01 至 2011-01-31
关键词:
Advisory CommitteesAnimalsAwardBiology of AgingBioluminescenceCancer CenterCellsCommitDental SchoolsDiseaseEnsureEquipmentEvaluationFluorescenceFundingGoalsGrowthHealthImageImageryIn VitroK22 AwardLabelLifeLocationMaintenanceMalignant NeoplasmsMedicalMichiganMonitorMusNeoplasm MetastasisReporterReportingResearchResearch PersonnelResearch Project GrantsScanningSourceSystemTNFRSF5 geneTechnologyTimeTissuesTrainingUnited States National Institutes of HealthUniversitiesWalkingage relatedangiogenesisanimal facilitybasebonecostdesignefficacy testingexperienceimprovedin vivomembermolecular imagingpublic health relevanceresearch studytherapeutic angiogenesistransmission process
中文摘要
描述(由申请人提供):本提案的目的是获得一种非侵入性3D定量分子成像系统,允许体内、体外和体外成像。该系统被称为来自Caliper生命科学公司的IVIS光谱,能够进行透射和反射荧光和生物发光成像。它具有10个窄带激发滤波器和18个窄带发射滤波器,允许在大波长区域扫描和多个报告器的评估。该设备允许在麻醉动物体内的深层组织源内的记者可视化。具体来说,细胞可以用特定的发光报告标记并注射到小鼠体内,并在小鼠体内确定其最终的定位和生长。具体的例子包括转移研究或血管生成的量化。该应用程序支持12名研究人员和13个r01的研究组合,一个P01中的4个项目,两个P50孢子中的3个项目,2个r21和1个K22奖,NIH主任奖和一个U奖,总共25个NIH资助的项目。该小组由多个系以及医学院和牙科学院的成员组成。目前,校园里有一个IVIS光谱系统,但距离癌症中心动物设施有15分钟的步行路程(对运输动物来说是一个特别的挑战,特别是在冬天),而且通常需要很长时间(几周)才能获得访问,这给计划体内实验带来了巨大的挑战,很难确定时间。购买该系统的主要理由是获得这项技术,以便更好地计划体内实验,因为机器时间较少拥挤,并且将设备放置在癌症中心大楼动物设施附近,便于大量研究人员使用。已经计划的项目将利用每年用户时间的87%,这表明对这种新设备的需求很高。研究项目与NIH改善健康的目标直接相关,包括癌症转移、癌症治疗、血管生成、骨生物学和年龄相关疾病的研究。这些设备将由经验丰富的技术人员和内部咨询委员会提供支持。一个吸引和培训新用户的系统已经到位,这样其他由nih资助的研究人员就可以从这些设备中受益。已承诺在最初四年为维护和技术费用提供大量机构支助,以确保该系统的长期生存能力(四年期间共计151,600美元)。在这段时间后,将建立一个基于用户的充值系统,以继续其长期使用。此外,还有机构承诺为设备提供空间。总之,使用这个尖端的成像系统将大大加快密歇根大学的研究步伐,为大量的nih资助的研究人员。
英文摘要
DESCRIPTION (provided by applicant): The objective of this proposal is to acquire a non-invasive 3D quantitative molecular imaging system that allows for in vivo, ex vivo and in vitro imaging. The system, called the IVIS Spectrum from Caliper LifeSciences, is capable of transmission and reflectance fluorescence and bioluminescence imaging. It has 10 narrow band excitation filters and 18 narrow band emission filters which allow for scanning over a large wavelength region and evaluation of multiple reporters. The equipment allows for visualization of reporters located within deep tissue sources in vivo in anesthetized animals. In concrete terms, cells can be labeled with specific luminescent reports and injected into mice and their eventual localization and growth identified in mice. Specific examples include metastasis studies or quantification of angiogenesis. This application supports 12 investigators and a research portfolio of 13 R01s, 4 projects in one P01, 3 projects in two P50 SPORES, 2 R21s and 1 each of a K22 award, NIH Director's Award, and project in a U award for a total of 25 NIH-funded projects. The group consists of members of multiple Departments and the Medical and Dental Schools. Currently, there is one IVIS Spectrum system on campus, but at a 15 minute walk from the Cancer Center animal facility (a particular challenge for transporting animals, especially in winter) and often has lengthy wait periods (several weeks) to obtain access resulting in great challenges to planning in vivo experiments that can be very hard to time. The principal rationale for purchase of this system is to gain access to this technology so that in vivo experiments can be better planned due to less congested access to machine time and to have the equipment in a location readily accessible to the Cancer Center Building animal facility for a large number of investigators. The projects already planned for will utilize 87% of the annual user time indicating the high demand for this new equipment. Research projects are directly related to NIH goals of improving health and include studies on cancer metastasis, cancer therapeutics, angiogenesis, bone biology and age-related disease. The equipment will be supported by an experienced technical staff and an internal advisory committee. A system to attract and train new users is in place so that other NIH-funded investigators will benefit from the equipment. Significant institutional support for both maintenance and technical costs has been committed for the initial four years to ensure long-term viability of the system (Total of $151,600 over 4 years). A user-based recharge system will be put into place after this time period to continue its long-term use. Additionally, there is institutional commitment of space for the equipment. In summary access to this cutting edge imaging system will greatly accelerate the pace of research at University of Michigan for a large number of NIH-funded investigators.
Public Health Relevance: We are requesting an imaging system that allows us to detect and quantify specific cells growing within living animals over long time periods. This will allow us to identify mechanisms of disease or monitor efficacy of test therapies. Ultimately, it will enable us to design or optimize treatments for disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms of Sensitivity and Resistance to the Kinase Inhibitor Cabozantinib
-
批准号:8788150
-
项目类别:
-
资助金额:$24.8万
-
财政年份:2014
-
负责人:Evan T Keller
-
依托单位:
Microfluidic PCR System for Single Cell Transcriptional Analysis
-
批准号:8446702
-
项目类别:
-
资助金额:$24.17万
-
财政年份:2013
-
负责人:Evan T Keller
-
依托单位:
Mechanisms of Prostate Cancer Dormancy in the Bone Marrow Niche
-
批准号:8333998
-
项目类别:
-
资助金额:$61.25万
-
财政年份:2011
-
负责人:Evan T Keller
-
依托单位:
Mechanisms of Prostate Cancer Dormancy in the Bone Marrow Niche
-
批准号:8713957
-
项目类别:
-
资助金额:$49.55万
-
财政年份:2011
-
负责人:Evan T Keller
-
依托单位:
Mechanisms of Prostate Cancer Dormancy in the Bone Marrow Niche
-
批准号:8536247
-
项目类别:
-
资助金额:$48.72万
-
财政年份:2011
-
负责人:Evan T Keller
-
依托单位:
Mechanisms of Prostate Cancer Dormancy in the Bone Marrow Niche
-
批准号:8213014
-
项目类别:
-
资助金额:$54.1万
-
财政年份:2011
-
负责人:Evan T Keller
-
依托单位:
Aging Rodent Core
-
批准号:8122845
-
项目类别:
-
资助金额:$9.34万
-
财政年份:2010
-
负责人:Evan T Keller
-
依托单位:
CORE--AGING TRANSGENIC RODENT/PATHOLOGY
-
批准号:6948014
-
项目类别:
-
资助金额:$5.8万
-
财政年份:2005
-
负责人:Evan T Keller
-
依托单位:
Prostate Cancer Metastasis Suppressor: Role of RKIP
-
批准号:6872148
-
项目类别:
-
资助金额:$25.09万
-
财政年份:2004
-
负责人:Evan T Keller
-
依托单位:
Project 3: The osteocyte-driven GDF15:GFRAL axis promotes prostate cancer bone metastasis
-
批准号:10427247
-
项目类别:
-
资助金额:$18.44万
-
财政年份:2004
-
负责人:Evan T Keller
-
依托单位:
The Biology of Prostate Cancer Skeletal Metastases
-
批准号:8854463
-
项目类别:
-
资助金额:$151.94万
-
财政年份:2004
-
负责人:Evan T Keller
-
依托单位:
Administrative Core
-
批准号:8854464
-
项目类别:
-
资助金额:$22.37万
-
财政年份:2004
-
负责人:Evan T Keller
-
依托单位:
Administrative Core
-
批准号:9163104
-
项目类别:
-
资助金额:$33.85万
-
财政年份:2004
-
负责人:Evan T Keller
-
依托单位:
The Biology of Prostate Cancer Skeletal Metastases
-
批准号:7282340
-
项目类别:
-
资助金额:$143.44万
-
财政年份:2004
-
负责人:Evan T Keller
-
依托单位:
Core B - Animal Core
-
批准号:10629277
-
项目类别:
-
资助金额:$35.24万
-
财政年份:2004
-
负责人:Evan T Keller
-
依托单位:
Animal Core
-
批准号:7659017
-
项目类别:
-
资助金额:$33.85万
-
财政年份:2004
-
负责人:Evan T Keller
-
依托单位:
Core A - Administrative Core
-
批准号:10427249
-
项目类别:
-
资助金额:$22.07万
-
财政年份:2004
-
负责人:Evan T Keller
-
依托单位:
Prostate Cancer Metastasis Suppressor: Role of RKIP
-
批准号:7195704
-
项目类别:
-
资助金额:$23.79万
-
财政年份:2004
-
负责人:Evan T Keller
-
依托单位:
Prostate Cancer Metastasis Suppressor: Role of RKIP
-
批准号:6776821
-
项目类别:
-
资助金额:$25.09万
-
财政年份:2004
-
负责人:Evan T Keller
-
依托单位:
Animal Core
-
批准号:8284226
-
项目类别:
-
资助金额:$33.58万
-
财政年份:2004
-
负责人:Evan T Keller
-
依托单位:
海外基金